CN Patent

CN114375191A — 非镇静的右美托咪定治疗方案

Assigned to Alces Co ltd · Expires 2022-04-19 · 4y expired

What this patent protects

本文公开了在不另外诱导显著镇静的情况下向人受试者施用相对高剂量的右美托咪定或其药学上可接受的盐的方法。所公开的方法特别适合于治疗激躁，尤其当与神经变性疾病和/或神经精神疾病诸如精神分裂症、双相型疾病诸如双相情感障碍或躁狂症、痴呆、抑郁或谵妄相关时。

USPTO Abstract

本文公开了在不另外诱导显著镇静的情况下向人受试者施用相对高剂量的右美托咪定或其药学上可接受的盐的方法。所公开的方法特别适合于治疗激躁，尤其当与神经变性疾病和/或神经精神疾病诸如精神分裂症、双相型疾病诸如双相情感障碍或躁狂症、痴呆、抑郁或谵妄相关时。

Drugs covered by this patent

Patent Metadata

Patent number
CN114375191A
Jurisdiction
CN
Classification
—
Expires
2022-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Alces Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.